DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
06 Setembro 2023 - 9:35AM
Business Wire
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company focused on developing novel treatments
for neurological disorders, today announced that Rick Pauls, its
President and CEO will be participating at Lake Street Capital
Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New
York, on September 14, 2023. Management will conduct one-on-one
meetings with investors during the conference.
To receive additional information or to schedule a one-on-one
meeting, please contact your Lake Street Capital Markets
representative.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases with a focus on acute
ischemic stroke. DiaMedica’s lead candidate DM199 is the first
pharmaceutically active and clinically studied recombinant
(synthetic) form of the KLK1 protein, an established therapeutic
modality in Asia for the treatment of acute ischemic stroke and
other vascular diseases. For more information visit our website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906375201/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
